Arvinas, Inc.
NASDAQ:ARVN
Overview | Financials
| Company Name | Arvinas, Inc. |
| Symbol | ARVN |
| Currency | USD |
| Price | 7.94 |
| Market Cap | 582,935,744 |
| Dividend Yield | 0% |
| 52-week-range | 5.9 - 29.61 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Dr. John G. Houston Ph.D. |
| Website | https://www.arvinas.com |
An error occurred while fetching data.
About Arvinas, Inc.
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD









